Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9952W HIGH $5.07
Volume
704.82 K
Value Traded
110.23 K
Short % Float
2.41%
-18.37%Week
-36.84%1 Month
-63.3%3 Month
-76.05%6 Month
-86.04%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.81 M
EPS (TTM)
-1.35
P/E Ratio
-
Ent. Value
370.12 K
Total Shares
9.01 M
Float Shares
6.85 M
Insiders
24.00%
Institutions
16.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LSTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Lisata Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lisata Therapeutics, Inc.
544Total events
26Upcoming
136Tier-1 (high impact)
2010 to 2043Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedcertepetideIP / Competition
USPTO grants new Method of Use patent for certepetide in pancreatic cancer and other solid tumors
pancreatic cancer and other solid tumorssource ↗
▲First Patient DosedMAR002Trial
First patient dosed in Phase 2 trial of MAR002 in acromegaly
Acromegalysource ↗
●Corporate ApprovalCorporate
Marea board and stockholders approved the acquisition; Lisata board approved
●Management ChangeCorporate
Dr. Josh Lehrer appointed COO and President of Lisata and CEO of Marea
▼Restructuring LayoffsCorporate
Lisata implements reduction in force of approximately 72% of full-time employees
◆IP Litigation RulingIP / Competition
Lisata files suit against Kuva Labs for breach of merger agreement
◆Pipeline PrioritizationCorporate
Lisata Board evaluates strategic alternatives including acquisition, merger, or liquidation
◆AcquisitionCorporate
Kuva Labs commences tender offer to acquire Lisata for $4.00/share plus CVR
▲Oral PresentationMAR002Presentation
MAR002 Phase 1 data presented at 2026 Endocrine Society Annual Meeting
acromegalysource ↗
◆Timing GuidancePresentation
Company expects to announce numerous milestones over next 1.5 years
◆AcquisitionCorporate
Waiver to Agreement and Plan of Merger between Kuva Labs and Lisata Therapeutics
▲Partnership / LicensecertepetideCorporate
Mutual termination of license agreement with Qilu Pharmaceutical for certepetide in Greater China
◆AcquisitionCorporate
Lisata enters binding term sheet to be acquired by Kuva Labs for $4.00 per share in all-cash tender offer
◆Trial InitiationTrial
OUD drug candidate targeted to enter Phase 1 human trials early next year
opioid use disordersource ↗
◆Full ResultscertepetideClinical Data
Final data from iLSTA study anticipated
locally advanced non-resectable pancreatic ductal adenocarcinomasource ↗
▲Breakthrough Therapy DesignationDesignation
Lisata wins 2025 BioTech Breakthrough Award for Overall BioPharma Solution of the Year
▲Topline ReadoutcertepetideClinical Data
ASCEND Phase 2b trial positive preliminary results: high dose group 6-month PFS 60.8% vs 25% placebo, ORR 45.2% vs 19%
metastatic pancreatic ductal adenocarcinomasource ↗
▲Partnership / LicensecertepetideCorporate
Catalent enters into global license agreement for certepetide in ADC platform
solid tumorssource ↗
▲Partnership / LicenseCorporate
Strategic alliance with GATC Health to use AI drug discovery platform
▲Preclinical PoCcertepetidePreclinical
Preclinical proof-of-concept for certepetide as ADC payload
solid tumorssource ↗
▲Oral PresentationcertepetidePresentation
Catalent presents preclinical data on certepetide as ADC payload at World ADC San Diego Conference
solid tumorssource ↗
◆Oral PresentationcertepetidePresentation
Preclinical data on iRGD peptides in SMARTag ADC platform at World ADC conference
solid tumorssource ↗
▲Partnership / LicensecertepetideCorporate
Global license agreement with Catalent for certepetide in ADCs
solid tumorssource ↗
▲Preclinical PoCcertepetidePreclinical
Preclinical proof-of-concept for iRGD peptide in SMARTag ADC platform
solid tumorssource ↗
◆Topline ReadoutcertepetideClinical Data
Topline data readout for BOLSTER first-line CCA
first-line cholangiocarcinomasource ↗
◆Enrollment CompleteLSTA1Trial
Enrollment completion expected for Qilu's Phase 2 trial of LSTA1 in mPDAC
metastatic pancreatic ductal adenocarcinomasource ↗
◆Poster PresentationcertepetidePresentation
Poster presentation of preliminary data from PDAC cohort at AACR Special Conference
pancreatic ductal adenocarcinomasource ↗
▲Topline ReadoutcertepetideClinical Data
Preliminary results from PDAC cohort announced
pancreatic ductal adenocarcinomasource ↗
◆Oral PresentationPresentation
Corporate overview presentation at H.C. Wainwright 27th Annual Global Investment Conference
●Oral PresentationcertepetidePresentation
Conference call to discuss financial results and business update
metastatic pancreatic ductal adenocarcinomasource ↗
▲Enrollment CompletecertepetideTrial
iLSTA trial enrollment completed
locally advanced non-resectable pancreatic ductal adenocarcinomasource ↗
▲Patent GrantedcertepetideIP / Competition
USPTO issued composition of matter patent for certepetide (US Patent No. 12,351,653) with expiration through March 2040
solid tumorssource ↗
▲Poster PresentationcertepetidePresentation
Updated preliminary data presented at ESMO-GI 2025
locally advanced non-resectable pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationcertepetidePresentation
Updated interim analyses from iLSTA presented at ESMO-GI Congress
locally advanced non-resectable pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationcertepetidePresentation
Preliminary Cohort B data presented at ESMO-GI Congress
metastatic pancreatic ductal adenocarcinomasource ↗
▲Topline ReadoutcertepetideClinical Data
Positive data reported from CENDIFOX trial
solid tumorssource ↗
▲Enrollment CompletecertepetideTrial
ASCEND Cohort B enrollment completed
metastatic pancreatic ductal adenocarcinomasource ↗
▲Oral PresentationcertepetidePresentation
Positive preliminary Cohort B results from ASCEND trial to be presented at ESMO GI
metastatic pancreatic cancersource ↗
◆Oral PresentationPresentation
Corporate overview presentation at 2025 BIO International Convention
Past FDA Catalysts and PDUFA Decisions
How LSTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-07-02 | Certepetide | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$27M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
2.2x
rNPV / MCap
Top 28%
Micro Cap(rank 185 of 658)
Percentile Rank
Lisata Therapeutics, Inc. carries a moderate pipeline score (45/100), with $2.9B risk-adjusted pipeline value, led by CLBS14 in Diabetes Mellitus (Phase 2), across $134B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLBS14 Monoclonal antibodyCompletedNCT02691247 | Diabetes Mellitus | Phase 2 | COMPLETED | 113 | Jan 1, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every LSTA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| certepetide OrphanRare Pediatric | pancreatic cancer | Phase 1/2a | 2025-09-29 | R0 resection rate: 50%; two year overall survival rate: 60%; pathologic partial response: 70%; median disease free survival: 12 monthsRead More | Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AZAB MOHAMMADDirector | Grant/Award | 19,200 19,200 held | $6.25 | 09/15/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in LSTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LSTA for Q2 2026. | ||||
LSTA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LSTA ranks across every disease it competes in
Competitive Position is a premium feature
See how LSTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLSTA News
LSTA▼ -2.6%today
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Lisata Therapeutics has received a new Method of Use patent for certepetide, aimed at treating pancreatic cancer and other solid tumors. This patent extends the company's intellectual property protection until May 2041, enhancing market exclusivity. Certepetide is designed to improve the effectiveness of anti-cancer drugs by facilitating their uptake in tumors.
Read more →LSTA▼ -14.3%on this newsshared move
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Marea Therapeutics has initiated its Phase 2 clinical trial for MAR002, a novel therapy for acromegaly, with the first patient dosed. The trial follows promising Phase 1 results showing effective IGF-1 suppression and the potential for biweekly dosing. MAR002 aims to improve treatment outcomes for patients who struggle with current therapies.
Read more →LSTAMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced that it will present data from the Phase 2b TYDAL study of MAR001 at the American Heart Association Scientific Sessions 2026. The study focuses on a monoclonal antibody targeting ANGPTL4, aimed at lowering triglycerides. The presentation is scheduled for November 9, 2026, in Chicago, Illinois.
Read more →LSTA▲ +18.4%on this news
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Lisata Therapeutics has announced the acquisition of Marea Therapeutics, focusing on developing innovative treatments for cardioendocrine diseases. The deal includes a $225 million private placement to fund key clinical trials for Marea's late-stage candidates, MAR001 and MAR002. This acquisition is expected to enhance Lisata's pipeline and address significant unmet medical needs.
Read more →LSTA▲ +9.6%on this news
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata Therapeutics has announced the termination of its merger agreement with Kuva Labs and has filed a lawsuit against them for breach of contract. To cut costs and preserve cash, the company has laid off about 72% of its workforce. Lisata's Board is currently evaluating strategic alternatives to enhance shareholder value, including potential mergers and acquisitions.
Read more →LSTALisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata Therapeutics has announced a tender offer by Kuva Labs Inc. to acquire all outstanding shares for $4.00 each, plus contingent value rights. The deal, which values Lisata at a premium, is recommended by its Board of Directors and is expected to close in Q3 2026, pending certain conditions. Additional cash payments may be available based on milestone achievements.
Read more →LSTAWAIVER TO AGREEMENT AND PLAN OF MERGER This WAIVER TO AGREEMENT AND PLAN OF MERGER (this " Waiver "), dated
Kuva Labs Inc., along with its wholly owned subsidiary Kuva Acquisition Corp. and Lisata Therapeutics, Inc., has executed a waiver to the agreement and plan of merger originally dated March 6, 2026. This waiver extends the time for commencing the Offer as stipulated in the merger agreement, indicating a cooperative approach among the parties involved. The document outlines the signing by key executives from all companies, reinforcing their commitment to the merger process.
Read more →LSTA▲ +20.6%on this news
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Lisata Therapeutics has entered into a definitive agreement to be acquired by Kuva Labs, Inc. Stockholders will receive $5.00 per share in cash and a contingent value right for potential additional payments. The board of directors unanimously recommends acceptance of the offer, which is expected to close in the second quarter of 2026, pending customary conditions.
Read more →LSTALisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additio
Lisata Therapeutics has entered into a definitive agreement for acquisition by Kuva Labs, Inc., under which Lisata stockholders will receive $5.00 per share in cash at closing, with the potential for additional compensation through a contingent value right. The transaction, recommended by Lisata's board, is expected to close in the second quarter of 2026, following the necessary tender conditions. Post-acquisition, Lisata will transition to a privately-held structure, with its stock delisted from Nasdaq.
Read more →LSTALisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata Therapeutics has mutually terminated its license agreement with Qilu Pharmaceutical for certepetide, regaining full development rights in Greater China. This decision allows Lisata to explore further development of its proprietary peptide product candidate. Qilu will continue its ongoing Phase 2 clinical study of certepetide in pancreatic cancer, and Lisata will negotiate for relevant study data.
Read more →LSTA▲ +86.6%on this news
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Lisata Therapeutics has entered a term sheet to be acquired by Kuva Labs for $4.00 per share in cash, representing an 85% premium over its recent stock price. Stockholders will also receive contingent value rights worth $1 per share upon achieving specific milestones. The acquisition is expected to enhance the development of Lisata's promising product candidate, certepetide.
Read more →LSTA▼ -12.3%on this news
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics reported its third quarter 2025 financial results, highlighting positive clinical data for certepetide from various trials. The company formed a strategic alliance with GATC Health for AI-driven drug discovery and entered a global license agreement with Catalent. Operating expenses decreased, and the company projects sufficient cash to fund operations into early 2027.
Read more →LSTALisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
Lisata Therapeutics has been awarded the 'Overall BioPharma Solution of the Year' at the BioTech Breakthrough Awards for its innovative CendR Platform technology. This recognition marks the second consecutive year for Lisata, which has achieved significant clinical results in treating advanced solid tumors. The company's approach aims to improve drug delivery and efficacy in cancer therapies, particularly for pancreatic cancer.
Read more →LSTA▼ -5.3%on this newsshared move
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Lisata Therapeutics announced positive preclinical results for certepetide, presented by its partner Catalent at the World ADC Conference. The data indicates that certepetide enhances the efficacy of antibody-drug conjugates (ADCs) while improving the distribution of cytotoxic agents within tumors. This reinforces Lisata's strategy to leverage certepetide's unique properties in cancer treatment.
Read more →LSTALisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
Lisata Therapeutics, a clinical-stage pharmaceutical company, announced it will report its third-quarter financial results for 2025 on November 6, 2025, followed by a conference call. The company specializes in innovative therapies for advanced solid tumors, particularly focusing on its investigational drug certepetide. Lisata has established significant partnerships and anticipates key milestones over the next one and a half years, with sufficient funding to support operations into early 2027.
Read more →LSTAForward-looking statements advisory This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation R
Lisata Therapeutics has issued a presentation highlighting forward-looking statements that pose substantial risks and uncertainties under the Private Securities Litigation Reform Act. The company focuses on developing therapies for cancer, notably its lead candidate, certepetide, which aims to improve treatment for solid tumors. Management outlines their financial stability, with a cash runway until early 2027. However, various factors, including regulatory challenges and market conditions, could impact future performance significantly.
Read more →LSTALisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics and Catalent have entered a global licensing agreement allowing Catalent to use Lisata's certepetide in antibody-drug conjugates (ADCs). This collaboration aims to develop targeted therapies for difficult-to-treat diseases, leveraging positive preclinical results. Lisata stands to receive significant milestone payments and revenue sharing from future sales.
Read more →LSTALisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Lisata Therapeutics announced promising preliminary results from the pancreatic cancer cohort of the Phase 1/2a CENDIFOX trial, evaluating certepetide combined with FOLFIRINOX. The trial showed a 50% R0 resection rate and a 60% two-year overall survival rate among patients. Findings will be presented at the AACR Special Conference, highlighting the potential of certepetide to improve treatment outcomes for pancreatic cancer.
Read more →LSTALisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. CEO David J. Mazzo, Ph.D., will provide a corporate overview through a pre-recorded presentation available on-demand starting September 5, 2025. The company is focused on developing therapies for advanced solid tumors and has promising product candidates.
Read more →About Lisata Therapeutics, Inc.
Headquarters110 ALLEN ROAD, BASKING RIDGE, NJ, 07920
BIOPHARMAWATCH ELITE PLUS
Trade the next LSTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime